TNSN96085A1 - Amides therapeutiques et compositions les contenant - Google Patents
Amides therapeutiques et compositions les contenantInfo
- Publication number
- TNSN96085A1 TNSN96085A1 TNTNSN96085A TNSN96085A TNSN96085A1 TN SN96085 A1 TNSN96085 A1 TN SN96085A1 TN TNSN96085 A TNTNSN96085 A TN TNSN96085A TN SN96085 A TNSN96085 A TN SN96085A TN SN96085 A1 TNSN96085 A1 TN SN96085A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compositions containing
- amides
- therapeutic amides
- therapeutic
- apolipoprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSES DE FORMULE (I) : DANS LAQUELLE X, Y et Z REPRESENTENT DIVERS SUBSTITUANTS. ELLE CONCERNE EGALEMENT UNE COMPOSITION PHARMACEUTIQUE RENFERMANT UN TEL COMPOSE. APPLICATION : UTILISATION DANS LA DIMINUTION DE LA SECRETION D'APOLIPOPROTEINE B ET DANS LE TRAITEMENT D'AFFECTIONS, TELLES QUE L'ATHEROSCLEROSE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1995/000448 WO1996040640A1 (fr) | 1995-06-07 | 1995-06-07 | DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B) |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN96085A1 true TNSN96085A1 (fr) | 2005-03-15 |
Family
ID=11004342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN96085A TNSN96085A1 (fr) | 1995-06-07 | 1996-06-06 | Amides therapeutiques et compositions les contenant |
Country Status (20)
Country | Link |
---|---|
US (1) | US5919795A (fr) |
KR (1) | KR100225713B1 (fr) |
AR (1) | AR003424A1 (fr) |
AT (1) | ATE233734T1 (fr) |
AU (1) | AU703493B2 (fr) |
BG (1) | BG62442B1 (fr) |
CO (1) | CO4440626A1 (fr) |
DE (1) | DE69529849T2 (fr) |
DK (1) | DK0832069T3 (fr) |
DZ (1) | DZ2045A1 (fr) |
IL (3) | IL135377A (fr) |
MA (1) | MA23895A1 (fr) |
MX (1) | MX9709914A (fr) |
OA (1) | OA10363A (fr) |
RO (1) | RO116897B1 (fr) |
RU (1) | RU2141478C1 (fr) |
TN (1) | TNSN96085A1 (fr) |
TR (1) | TR199600481A2 (fr) |
TW (1) | TW476756B (fr) |
YU (1) | YU35296A (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0902785B1 (fr) * | 1996-04-30 | 2002-09-04 | Pfizer Inc. | Procedes et intermediaires pour la preparation de 2-(2h- 1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolein-6-yl]-amide d'acide 4'-trifluoromethylbiphenyl-2-carboxylique |
JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
CA2325358C (fr) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b |
ES2240420T3 (es) * | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
US6953671B2 (en) * | 2001-02-23 | 2005-10-11 | The Trustees Of Columbia University In The City Of New York | Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action |
ES2307799T3 (es) | 2001-06-28 | 2008-12-01 | Pfizer Products Inc. | Benzotiofenos, benzofuranos e indoles sustituidos con triamida como inhibidores de la proteina de transferencia de trigliceridos microsomal (mtp) y/o la secrecion de la apoliproteina b (apo b). |
US7241774B2 (en) * | 2002-03-13 | 2007-07-10 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
EP2428516A1 (fr) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
EP1687299A1 (fr) * | 2003-11-20 | 2006-08-09 | Eli Lilly And Company | Composes heterocycliques utilises comme modulateurs des recepteurs actives proliferateurs du peroxysome (ppar), utiles dans le traitement et/ou la prevention de troubles modules par un ppar |
AU2005214159A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | 4−(2−メチルフェニル)ベンゾトリフルオライドの製造方法 |
EP1877369B1 (fr) * | 2005-04-19 | 2013-07-10 | Surface Logix, Inc. | Inhibiteurs des secretions microsomales des apo-b et des proteines de transfert des triglycerides |
WO2006129193A2 (fr) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale |
WO2007112754A2 (fr) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Composition pharmaceutique |
EP3502255A1 (fr) * | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Composition pharmaceutique |
GB0619176D0 (en) * | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
EP2076597A2 (fr) * | 2006-10-09 | 2009-07-08 | Santaris Pharma A/S | Composés antagonistes de l'arn pour la modulation de pcsk9 |
WO2008045564A2 (fr) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Composés de carboxamide et leur utilisation |
JP2010521193A (ja) * | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー/エス | Apo−b100発現の阻害のためのrnaアンタゴニスト化合物 |
DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
US20110054011A1 (en) * | 2007-08-30 | 2011-03-03 | Mccullagh Keith | RNA Antagonist Compounds for the Modulation of FABP4/AP2 |
US8440637B2 (en) | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
RU2010128543A (ru) | 2007-12-11 | 2012-01-20 | Сайтопатфайндер, Инк. (Jp) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
CA2717792A1 (fr) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de maladies associees aux microarn |
WO2010012667A1 (fr) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Modulation à médiation par micro-arn de facteurs stimulateurs de colonies |
EP2356094A1 (fr) * | 2008-10-29 | 2011-08-17 | F. Hoffmann-La Roche AG | Nouveaux dérivés d'amides phényliques ou d'amides pyridyliques et leur utilisation en tant agonistes de gpbar1 |
WO2010093601A1 (fr) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees |
EP2421970B1 (fr) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons |
US20100280067A1 (en) * | 2009-04-30 | 2010-11-04 | Pakala Kumara Savithru Sarma | Inhibitors of acetyl-coa carboxylase |
WO2010127208A1 (fr) * | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibiteurs de l'acétyl-coa carboxylase |
EP2456870A1 (fr) | 2009-07-21 | 2012-05-30 | Santaris Pharma A/S | Oligomères anti-sens ciblant pcsk9 |
CA2817093A1 (fr) * | 2010-11-15 | 2012-05-24 | Abbvie Inc. | Inhibiteurs de nampt |
DK3013959T3 (da) | 2013-06-27 | 2020-02-17 | Roche Innovation Ct Copenhagen As | Antisense-oligomerer og konjugater målrettet pcsk9 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
DK410183A (da) * | 1982-09-10 | 1984-03-11 | Wellcome Found | 2-(substitueret-phenyl)-benzoesyrederivater, fremgangsmaade til deres fremstilling samt deres anvendelse |
GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
SK65499A3 (en) * | 1996-11-27 | 2001-05-10 | Pfizer | Apo b-secretion/mtp inhibitory amides |
-
1995
- 1995-06-07 AT AT95918722T patent/ATE233734T1/de not_active IP Right Cessation
- 1995-06-07 DE DE69529849T patent/DE69529849T2/de not_active Expired - Fee Related
- 1995-06-07 DK DK95918722T patent/DK0832069T3/da active
- 1995-06-07 US US08/952,507 patent/US5919795A/en not_active Expired - Fee Related
- 1995-06-07 MX MX9709914A patent/MX9709914A/es not_active IP Right Cessation
-
1996
- 1996-04-19 TW TW085104696A patent/TW476756B/zh not_active IP Right Cessation
- 1996-05-30 IL IL13537796A patent/IL135377A/en not_active IP Right Cessation
- 1996-05-30 IL IL13537596A patent/IL135375A/en not_active IP Right Cessation
- 1996-05-30 IL IL13537696A patent/IL135376A/en not_active IP Right Cessation
- 1996-06-03 AR ARP960102871A patent/AR003424A1/es unknown
- 1996-06-05 BG BG100637A patent/BG62442B1/bg unknown
- 1996-06-05 DZ DZ960089A patent/DZ2045A1/fr active
- 1996-06-05 KR KR1019960020168A patent/KR100225713B1/ko not_active IP Right Cessation
- 1996-06-06 TN TNTNSN96085A patent/TNSN96085A1/fr unknown
- 1996-06-06 TR TR96/00481A patent/TR199600481A2/xx unknown
- 1996-06-06 MA MA24265A patent/MA23895A1/fr unknown
- 1996-06-06 AU AU54784/96A patent/AU703493B2/en not_active Ceased
- 1996-06-06 YU YU35296A patent/YU35296A/sh unknown
- 1996-06-06 RU RU96111018A patent/RU2141478C1/ru not_active IP Right Cessation
- 1996-06-07 RO RO96-01181A patent/RO116897B1/ro unknown
- 1996-06-07 OA OA60837A patent/OA10363A/en unknown
- 1996-06-07 CO CO96029732A patent/CO4440626A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BG100637A (bg) | 1997-03-31 |
AR003424A1 (es) | 1998-08-05 |
TR199600481A2 (tr) | 1996-12-21 |
AU703493B2 (en) | 1999-03-25 |
RO116897B1 (ro) | 2001-07-30 |
CO4440626A1 (es) | 1997-05-07 |
DZ2045A1 (fr) | 2002-07-21 |
AU5478496A (en) | 1996-12-19 |
IL135375A0 (en) | 2001-05-20 |
BG62442B1 (bg) | 1999-11-30 |
DK0832069T3 (da) | 2003-04-22 |
YU35296A (sh) | 1999-06-15 |
DE69529849D1 (de) | 2003-04-10 |
MX9709914A (es) | 1998-03-31 |
KR100225713B1 (ko) | 1999-10-15 |
US5919795A (en) | 1999-07-06 |
IL135377A0 (en) | 2001-05-20 |
DE69529849T2 (de) | 2003-09-04 |
KR970003589A (ko) | 1997-01-28 |
ATE233734T1 (de) | 2003-03-15 |
IL135376A0 (en) | 2001-05-20 |
IL135376A (en) | 2001-05-20 |
OA10363A (en) | 2001-11-15 |
IL135375A (en) | 2001-07-24 |
TW476756B (en) | 2002-02-21 |
MA23895A1 (fr) | 1996-12-31 |
RU2141478C1 (ru) | 1999-11-20 |
IL135377A (en) | 2001-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN96085A1 (fr) | Amides therapeutiques et compositions les contenant | |
TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99053A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN99006A1 (fr) | 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99055A1 (fr) | Derives bicycliques d'acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97193A1 (fr) | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN00191A1 (fr) | Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie | |
TNSN96172A1 (fr) | Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97208A1 (fr) | Prevention de la perte et restauration de la masse osseuse par certains agonistes des prostaglandines | |
TNSN97139A1 (fr) | Derives d'acides d'arylsulfonylaminohydroxamiques | |
TNSN98194A1 (fr) | Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
FR2430410A1 (fr) | Phenethanolamines et compositions pharmaceutiques en contenant | |
TNSN98112A1 (fr) | Composes dipeptidiques | |
TNSN01091A1 (fr) | Derives bicycliques nouveaux, compositions les contenant et leur utilisation pour le traitement d'une croissance cellulaire anormale | |
NZ237023A (en) | 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions | |
TNSN98140A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN96104A1 (fr) | Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant | |
MA24729A1 (fr) | Macrolides nouveaux. | |
TNSN98082A1 (fr) | DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A. | |
TNSN98210A1 (fr) | Trifluoromethylethers cycliques a fonction piperidinylaminomethyle, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
TNSN98036A1 (fr) | Derives d'acide hexanoique nouveaux |